Cargando…
The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age
BACKGROUND: Fluticasone propionate 50 μg/salmeterol xinafoate 25 μg (FP/SAL) is widely used in adults and children with asthma, but there is sparse information on its use in very young children. METHODS: This was a randomized, double‐blind, multicentre, controlled trial conducted in children aged 8 ...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850202/ https://www.ncbi.nlm.nih.gov/pubmed/30556939 http://dx.doi.org/10.1111/pai.13010 |
_version_ | 1783469374801182720 |
---|---|
author | Yoshihara, Shigemi Tsubaki, Toshikazu Ikeda, Masanori Lenney, Warren Tomiak, Richard Hattori, Takako Hashimoto, Kenichi Soutome, Toru Kato, Shihona |
author_facet | Yoshihara, Shigemi Tsubaki, Toshikazu Ikeda, Masanori Lenney, Warren Tomiak, Richard Hattori, Takako Hashimoto, Kenichi Soutome, Toru Kato, Shihona |
author_sort | Yoshihara, Shigemi |
collection | PubMed |
description | BACKGROUND: Fluticasone propionate 50 μg/salmeterol xinafoate 25 μg (FP/SAL) is widely used in adults and children with asthma, but there is sparse information on its use in very young children. METHODS: This was a randomized, double‐blind, multicentre, controlled trial conducted in children aged 8 months to 4 years. During a 2‐week run‐in period, they all received FP twice daily. At randomization, they commenced FP/SAL or FP twice daily for 8 weeks. All were then given FP/SAL only, in a 16‐week open‐label study continuation. Medications were inhaled through an AeroChamber Plus with attached face mask. The primary end‐point was mean change in total asthma symptom scores from baseline to the last 7 days of the double‐blind period. Analyses were undertaken in all children randomized to treatment and who received at least one dose of study medication. RESULTS: Three hundred children were randomized 1:1 to receive FP/SAL or FP. Mean change from baseline in total asthma symptom scores was –3.97 for FP/SAL and –3.01 with FP. The between‐group difference was not statistically significant (P = 0.21; 95% confidence interval: −2.47, 0.54). No new safety signals were seen with FP/SAL. CONCLUSION: This is the first randomized, double‐blind study of this size to evaluate FP/SAL in very young children with asthma. FP/SAL did not show superior efficacy to FP; no clear add‐on effect of SAL was demonstrated. No clinically significant differences in safety were noted with FP/SAL usage. |
format | Online Article Text |
id | pubmed-6850202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68502022019-11-18 The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age Yoshihara, Shigemi Tsubaki, Toshikazu Ikeda, Masanori Lenney, Warren Tomiak, Richard Hattori, Takako Hashimoto, Kenichi Soutome, Toru Kato, Shihona Pediatr Allergy Immunol ORIGINAL ARTICLES BACKGROUND: Fluticasone propionate 50 μg/salmeterol xinafoate 25 μg (FP/SAL) is widely used in adults and children with asthma, but there is sparse information on its use in very young children. METHODS: This was a randomized, double‐blind, multicentre, controlled trial conducted in children aged 8 months to 4 years. During a 2‐week run‐in period, they all received FP twice daily. At randomization, they commenced FP/SAL or FP twice daily for 8 weeks. All were then given FP/SAL only, in a 16‐week open‐label study continuation. Medications were inhaled through an AeroChamber Plus with attached face mask. The primary end‐point was mean change in total asthma symptom scores from baseline to the last 7 days of the double‐blind period. Analyses were undertaken in all children randomized to treatment and who received at least one dose of study medication. RESULTS: Three hundred children were randomized 1:1 to receive FP/SAL or FP. Mean change from baseline in total asthma symptom scores was –3.97 for FP/SAL and –3.01 with FP. The between‐group difference was not statistically significant (P = 0.21; 95% confidence interval: −2.47, 0.54). No new safety signals were seen with FP/SAL. CONCLUSION: This is the first randomized, double‐blind study of this size to evaluate FP/SAL in very young children with asthma. FP/SAL did not show superior efficacy to FP; no clear add‐on effect of SAL was demonstrated. No clinically significant differences in safety were noted with FP/SAL usage. John Wiley and Sons Inc. 2019-02-06 2019-03 /pmc/articles/PMC6850202/ /pubmed/30556939 http://dx.doi.org/10.1111/pai.13010 Text en © 2018 The Authors. Pediatric Allergy and Immunology Published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | ORIGINAL ARTICLES Yoshihara, Shigemi Tsubaki, Toshikazu Ikeda, Masanori Lenney, Warren Tomiak, Richard Hattori, Takako Hashimoto, Kenichi Soutome, Toru Kato, Shihona The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age |
title | The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age |
title_full | The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age |
title_fullStr | The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age |
title_full_unstemmed | The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age |
title_short | The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age |
title_sort | efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850202/ https://www.ncbi.nlm.nih.gov/pubmed/30556939 http://dx.doi.org/10.1111/pai.13010 |
work_keys_str_mv | AT yoshiharashigemi theefficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT tsubakitoshikazu theefficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT ikedamasanori theefficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT lenneywarren theefficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT tomiakrichard theefficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT hattoritakako theefficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT hashimotokenichi theefficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT soutometoru theefficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT katoshihona theefficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT yoshiharashigemi efficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT tsubakitoshikazu efficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT ikedamasanori efficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT lenneywarren efficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT tomiakrichard efficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT hattoritakako efficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT hashimotokenichi efficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT soutometoru efficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage AT katoshihona efficacyandsafetyoffluticasonesalmeterolcomparedtofluticasoneinchildrenyoungerthanfouryearsofage |